Upfront treatment of high-risk neuroblastoma with a combination of 131I-MIBG and topotecan

Keyphrases

• Topotecan 100%
• High-risk Neuroblastoma 100%
• Upfront Treatment 100%
• 131I-MIBG 100%
• Newly Diagnosed 42%
• Myeloablative Therapy 42%
• Autologous Stem Cell Transplantation (auto-SCT) 42%
• Neuroblastoma 28%
• Primary Tumor 28%
• Activity Level 28%
• Objective Response Rate 28%
• Gigas 28%
• Topoisomerase 28%
• Becquerel 28%
• Tumor 14%
• Bone Marrow 14%
• Combination Therapy 14%
• Induction Treatment 14%
• Stem Cells 14%
• Radiosensitization 14%
• Iodine-131 (131I) 14%
• Platelets 14%
• Neutrophils 14%
• Administered Activity 14%
• Hematologic 14%
• 123I-MIBG 14%
• Hematotoxicity 14%
• Second Course 14%
• Hemoglobin 14%
• Course Standards 14%
• Surgery Therapy 14%
• Antitumor Effect 14%
• Phase I Study 14%
• Working Diagnosis 14%
• Grade Four 14%

Medicine and Dentistry

• Ganglioneuroblastoma 100%
• (3 Iodobenzyl)guanidine I 131 100%
• Topotecan 100%
• Autologous Stem Cell Transplantation 42%
• Primary Tumor 28%
• Topoisomerase 28%
• Neoplasm 14%
• In Vitro 14%
• Combination Therapy 14%
• Tumor 14%
• Iodine 131 14%
• Radiosensitizer 14%
• (3 Iodobenzyl)guanidine 14%
• Platelet 14%
• Peripheral Blood Stem Cell Collection 14%
• Hemoglobins 14%
• Neutrophil 14%